Publications searcher

The science produced by our scientists is very important. In 2022, 1,629 papers were published in scientific journals with a global impact factor of over 15,000 points.

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.

PMID: 20679609
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2010
Reference: J Clin Oncol. 2010 Sep 1;28(25):3922-8. Epub 2010 Aug 2.
Impact factor: 17.793
Publication type: Paper in international publication
Authors: Cortes, Javier, Vahdat, Linda, Blum, Joanne L, Twelves, Chris, Campone, Mario, Roche, Henri, Bachelot, Thomas, Awada, Ahmad, Paridaens, Robert, Goncalves, Anthony et al.
DOI: 10.1200/JCO.2009.25.8467

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.

PMID: 20679609
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2010
Reference: J Clin Oncol. 2010 Sep 1;28(25):3922-8. Epub 2010 Aug 2.
Impact factor:
Publication type: Paper in international publication
Authors: Allison, Mary Ann; Ashworth, Simon; Awada, Ahmad; Bachelot, Thomas; Blum, Joanne L; Campone, Mario; Cole, Patricia E; Cortes, Javier; Fang, Fang; Goncalves, Anthony et al.
DOI: 10.1200/JCO.2009.25.8467

Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer.

PMID: 19577864
Journal: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Year: 2010
Reference: Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1085-91. doi: 10.1016/j.ijrobp.2009.03.024. Epub 2009 Jul 4.
Impact factor: 4.592
Publication type: Paper in international publication
Authors: Carles, Joan, Nogue, Miguel, Sole, Josep M, Foro, Palmira, Domenech, Montserrat, Suarez, Marta, Gallardo, Enrique, Garcia, Dario, Ferrer, Ferran, Gelabert-Mas, Antoni et al.
DOI: 10.1016/j.ijrobp.2009.03.024

Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer.

PMID: 19577864
Journal: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Year: 2010
Reference: Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1085-91. doi: 10.1016/j.ijrobp.2009.03.024. Epub 2009 Jul 4.
Impact factor:
Publication type: Paper in international publication
Authors: Carles, Joan; Domenech, Montserrat; Fabregat, Xavier; Ferrer, Ferran; Foro, Palmira; Gallardo, Enrique; Garcia, Dario; Gayo, Javier; Gelabert-Mas, Antoni; Nogue, Miguel et al.
DOI: 10.1016/j.ijrobp.2009.03.024

Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy.

PMID: 20124182
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2010
Reference: J Clin Oncol. 2010 Mar 1;28(7):1138-44. Epub 2010 Feb 1.
Impact factor: 17.793
Publication type: Paper in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1200/JCO.2009.24.2024

Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy.

PMID: 20124182
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2010
Reference: J Clin Oncol. 2010 Mar 1;28(7):1138-44. Epub 2010 Feb 1.
Impact factor:
Publication type: Paper in international publication
Authors: ; ; ; ; ; ; ; ; ; et al.
DOI: 10.1200/JCO.2009.24.2024

Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial.

PMID: 20185783
Journal: STROKE
Year: 2010
Reference: Stroke. 2010 Apr;41(4):707-11. Epub 2010 Feb 25.
Impact factor: 7.041
Publication type: Paper in international publication
Authors: Buda, M, Levine, Steven R, Johnston, Karen C, Buchsbaum, Richard, Levy, Gilberto, Levin, Bruce, Lyden, P, Hemmen, T, Meyer, B, Chacon, M et al.
DOI: 10.1161/STROKEAHA.109.572040

Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial.

PMID: 20185783
Journal: STROKE
Year: 2010
Reference: Stroke. 2010 Apr;41(4):707-11. Epub 2010 Feb 25.
Impact factor:
Publication type: Paper in international publication
Authors: Abraham, A; Acosta, I; Adams, A; Albers, G; Albright, K; Alderman, A; Alexandrov, A; Alt, J; Amory, C; Arbing, R et al.
DOI: 10.1161/STROKEAHA.109.572040

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.

PMID: 20498403
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2010
Reference: J Clin Oncol. 2010 Jul 10;28(20):3239-47. Epub 2010 May 24.
Impact factor: 17.793
Publication type: Paper in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1200/JCO.2008.21.6457

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.

PMID: 20498403
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2010
Reference: J Clin Oncol. 2010 Jul 10;28(20):3239-47. Epub 2010 May 24.
Impact factor:
Publication type: Paper in international publication
Authors: ; ; ; ; ; ; ; ; ; et al.
DOI: 10.1200/JCO.2008.21.6457

Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast Cancer.

PMID: 20299316
Journal: Clinical Breast Cancer
Year: 2010
Reference: Clin Breast Cancer. 2010 Apr;10(2):160-3.
Impact factor: 2.065
Publication type: Paper in international publication
Authors: , , , , , et al.
DOI: 10.3816/CBC.2010.n.023

Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast Cancer.

PMID: 20299316
Journal: Clinical Breast Cancer
Year: 2010
Reference: Clin Breast Cancer. 2010 Apr;10(2):160-3.
Impact factor:
Publication type: Paper in international publication
Authors: ; ; ; ; ; et al.
DOI: 10.3816/CBC.2010.n.023

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.

PMID: 19844788
Journal: BREAST CANCER RESEARCH AND TREATMENT
Year: 2010
Reference: Breast Cancer Res Treat. 2010 Jan;119(2):379-90.
Impact factor: 4.696
Publication type: Paper in international publication
Authors: Bandaru, Raj, Liu, WeiHua, Gardner, Humphrey, Semiglazov, Vladimir, Watson, Mark, Hunt, Kelly, Olson, John, Baselga, Jose, Steinseifer, Jutta, Evans, Dean B et al.
DOI: 10.1007/s10549-009-0575-y

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.

PMID: 19844788
Journal: BREAST CANCER RESEARCH AND TREATMENT
Year: 2010
Reference: Breast Cancer Res Treat. 2010 Jan;119(2):379-90.
Impact factor:
Publication type: Paper in international publication
Authors: Bandaru, Raj; Baselga, Jose; Crowder, Robert; Davies, Sherri; DeSchryver, Katherine; Ellis, Matthew J; Evans, Dean B; Gardner, Humphrey; Hoog, Jeremy; Hunt, Kelly et al.
DOI: 10.1007/s10549-009-0575-y

Photosensitivity in immunocompromised patients receiving long-term therapy with oral voriconazole.

PMID: 20431387
Journal: PEDIATRIC INFECTIOUS DISEASE JOURNAL
Year: 2010
Reference: Pediatr Infect Dis J. 2010 May;29(5):480-1.
Impact factor: 3.064
Publication type: Letter or abstract
Authors: Frick, Marie Antoinette, Soler-Palacin, Pere, Martin Nalda, Andrea, Guarner, Maria Espiau, Nadal, Concepcio Figueras et al.
DOI: 10.1097/INF.0b013e3181d60a82

Photosensitivity in immunocompromised patients receiving long-term therapy with oral voriconazole.

PMID: 20431387
Journal: PEDIATRIC INFECTIOUS DISEASE JOURNAL
Year: 2010
Reference: Pediatr Infect Dis J. 2010 May;29(5):480-1.
Impact factor:
Publication type: Letter or abstract
Authors: Frick, Marie Antoinette; Guarner, Maria Espiau; Martin Nalda, Andrea; Nadal, Concepcio Figueras; Soler-Palacin, Pere et al.
DOI: 10.1097/INF.0b013e3181d60a82

Physiopathology of splanchnic vasodilation in portal hypertension.

PMID: 21160999
Journal: World journal of hepatology
Year: 2010
Reference: World J Hepatol. 2010 Jun 27;2(6):208-20.
Impact factor:
Publication type: Letter or abstract
Authors: Martell, Maria, Coll, Mar, Ezkurdia, Nahia, Raurell, Imma, Genesca, Joan et al.
DOI: 10.4254/wjh.v2.i6.208

Physiopathology of splanchnic vasodilation in portal hypertension.

PMID: 21160999
Journal: World journal of hepatology
Year: 2010
Reference: World J Hepatol. 2010 Jun 27;2(6):208-20.
Impact factor:
Publication type: Letter or abstract
Authors: Coll, Mar; Ezkurdia, Nahia; Genesca, Joan; Martell, Maria; Raurell, Imma et al.
DOI: 10.4254/wjh.v2.i6.208

PI3K-based molecular signatures link high PI3K pathway activity with low ER levels in ER(+) breast cancer.

PMID: 21142884
Journal: Expert Review of Proteomics
Year: 2010
Reference: Expert Rev Proteomics. 2010 Dec;7(6):819-21.
Impact factor: 3.57
Publication type: Review in international publication
Authors: Villanueva, Josep, Sanchez, Alex et al.
DOI: 10.1586/epr.10.103

PI3K-based molecular signatures link high PI3K pathway activity with low ER levels in ER(+) breast cancer.

PMID: 21142884
Journal: Expert Review of Proteomics
Year: 2010
Reference: Expert Rev Proteomics. 2010 Dec;7(6):819-21.
Impact factor:
Publication type: Review in international publication
Authors: Sanchez, Alex; Villanueva, Josep et al.
DOI: 10.1586/epr.10.103

[Pilot study on the diode laser in stapes surgery].

PMID: 20409508
Journal: Acta Otorrinolaringológica Española
Year: 2010
Reference: Acta Otorrinolaringol Esp. 2010 Nov-Dec;61(6):434-6. doi: 10.1016/j.otorri.2010.02.006. Epub 2010 Apr 20.
Impact factor: 0
Publication type: Letter whit IF
Authors: Navarrete, Maria Luisa, Boemo, Rafael, Darwish, Mohamed, Monzon, Jesus, Rojas, Pedro et al.
DOI: 10.1016/j.otorri.2010.02.006

[Pilot study on the diode laser in stapes surgery].

PMID: 20409508
Journal: Acta Otorrinolaringológica Española
Year: 2010
Reference: Acta Otorrinolaringol Esp. 2010 Nov-Dec;61(6):434-6. doi: 10.1016/j.otorri.2010.02.006. Epub 2010 Apr 20.
Impact factor:
Publication type: Letter whit IF
Authors: Boemo, Rafael; Darwish, Mohamed; Monzon, Jesus; Navarrete, Maria Luisa; Rojas, Pedro et al.
DOI: 10.1016/j.otorri.2010.02.006

Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke.

PMID: 20538694
Journal: STROKE
Year: 2010
Reference: Stroke. 2010 Jul;41(7):1528-35. Epub 2010 Jun 10.
Impact factor: 7.041
Publication type: Paper in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1161/STROKEAHA.110.584623

Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke.

PMID: 20538694
Journal: STROKE
Year: 2010
Reference: Stroke. 2010 Jul;41(7):1528-35. Epub 2010 Jun 10.
Impact factor:
Publication type: Paper in international publication
Authors: ; ; ; ; ; ; ; ; ; et al.
DOI: 10.1161/STROKEAHA.110.584623

Publications

Publications searcher

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.

Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer.

Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer.

Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy.

Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy.

Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial.

Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial.

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.

Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast Cancer.

Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast Cancer.

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.

Photosensitivity in immunocompromised patients receiving long-term therapy with oral voriconazole.

Photosensitivity in immunocompromised patients receiving long-term therapy with oral voriconazole.

Physiopathology of splanchnic vasodilation in portal hypertension.

Physiopathology of splanchnic vasodilation in portal hypertension.

PI3K-based molecular signatures link high PI3K pathway activity with low ER levels in ER(+) breast cancer.

PI3K-based molecular signatures link high PI3K pathway activity with low ER levels in ER(+) breast cancer.

[Pilot study on the diode laser in stapes surgery].

[Pilot study on the diode laser in stapes surgery].

Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke.

Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke.

Patronage:

Collaborating:

Accreditations: